[go: up one dir, main page]

CL2014002796A1 - Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal. - Google Patents

Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal.

Info

Publication number
CL2014002796A1
CL2014002796A1 CL2014002796A CL2014002796A CL2014002796A1 CL 2014002796 A1 CL2014002796 A1 CL 2014002796A1 CL 2014002796 A CL2014002796 A CL 2014002796A CL 2014002796 A CL2014002796 A CL 2014002796A CL 2014002796 A1 CL2014002796 A1 CL 2014002796A1
Authority
CL
Chile
Prior art keywords
polymeric material
attacks
intestinal
susceptible
delayed
Prior art date
Application number
CL2014002796A
Other languages
English (en)
Inventor
González Roberto Carlos Bravo
Thomas Buser
Frédéric Jean-Claude Goutte
Abdul Waseh Basit
Felipe José Oliveria Varum
Ana Cristina Freire
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CL2014002796A1 publication Critical patent/CL2014002796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CL2014002796A 2012-04-30 2014-10-17 Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal. CL2014002796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
CL2014002796A1 true CL2014002796A1 (es) 2015-02-06

Family

ID=46025554

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014002795A CL2014002795A1 (es) 2012-04-30 2014-10-17 Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion.
CL2014002796A CL2014002796A1 (es) 2012-04-30 2014-10-17 Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014002795A CL2014002795A1 (es) 2012-04-30 2014-10-17 Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion.

Country Status (41)

Country Link
US (6) US9364440B2 (es)
EP (6) EP2659881B1 (es)
JP (2) JP6621662B2 (es)
KR (6) KR20190127986A (es)
CN (5) CN104271113B (es)
AR (1) AR090898A1 (es)
AU (4) AU2013255914B2 (es)
BR (3) BR112014026935A2 (es)
CA (4) CA3052460C (es)
CL (2) CL2014002795A1 (es)
CO (2) CO7151506A2 (es)
CR (4) CR20190246A (es)
CU (1) CU24304B1 (es)
CY (4) CY1120215T1 (es)
DK (5) DK2659881T3 (es)
EA (2) EA032811B1 (es)
ES (6) ES2987408T3 (es)
GE (4) GEP201706736B (es)
HR (2) HRP20180068T1 (es)
HU (5) HUE036187T2 (es)
JO (6) JOP20200144A1 (es)
LT (5) LT2659881T (es)
ME (2) ME03641B (es)
MX (4) MX362529B (es)
MY (3) MY169088A (es)
NO (1) NO2659881T3 (es)
NZ (3) NZ629260A (es)
PE (3) PE20150129A1 (es)
PH (2) PH12014502339B1 (es)
PL (5) PL2659881T3 (es)
PT (5) PT2659881T (es)
RS (5) RS56839B1 (es)
SA (2) SA115370043B1 (es)
SG (2) SG11201406799XA (es)
SI (5) SI2659881T1 (es)
SM (5) SMT201800095T1 (es)
TN (2) TN2014000441A1 (es)
TR (3) TR201905226T4 (es)
TW (3) TWI700102B (es)
UY (1) UY34772A (es)
WO (2) WO2013164315A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2659881B1 (en) * 2012-04-30 2017-11-29 Tillotts Pharma Ag A delayed release drug formulation
CU24342B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
TWI688411B (zh) * 2013-02-22 2020-03-21 日商志瑞亞新藥工業股份有限公司 腸溶錠
EP3542791A1 (en) 2013-10-29 2019-09-25 Tillotts Pharma AG A delayed release drug formulation
EA030615B1 (ru) 2013-12-24 2018-08-31 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор бримонидина для местного применения
ES2898930T3 (es) 2015-06-01 2022-03-09 Xeno Biosciences Inc Composiciones para usar en la modulación de la microbiota intestinal y el manejo del peso
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
CA3045011A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
EP3768302A4 (en) 2018-03-20 2021-12-15 Synthetic Biologics, Inc. INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
MX2020009900A (es) * 2018-03-23 2021-01-08 Palatin Technologies Inc Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662901B1 (en) * 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3666262B1 (en) * 2018-12-10 2021-11-10 Aphaia IP AG Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines
CN111617047B (zh) * 2019-02-27 2021-06-22 广州喜鹊医药有限公司 一种含tbn或其盐或其水合物的药物组合物及其制备方法
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
MX2022001865A (es) * 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
US20230301927A1 (en) * 2019-11-13 2023-09-28 Ethypharm Process for producing an orally administered pharmaceutical composition with colonic delivery
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN118806729A (zh) * 2024-06-18 2024-10-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
CA2148465C (en) * 1992-11-06 1999-11-02 Minenobu Okayama Oral pharmaceutical preparation releasable in the lower digestive tract
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) * 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CA2448068A1 (en) 2001-05-25 2002-12-05 Hiroyuki Mizuno Drug preparations
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2002361495A1 (en) 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20100285123A1 (en) 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
WO2008068584A2 (en) * 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
JPWO2008117814A1 (ja) * 2007-03-26 2010-07-15 帝國製薬株式会社 大腸送達用経口製剤
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
SMT202100223T1 (it) 2009-06-15 2021-05-07 Amarin Pharmaceuticals Ie Ltd Composizioni e metodi per abbassare i trigliceridi senza aumentare i livelli di ldl-c in un soggetto in terapia concomitante con statine
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
WO2013035081A2 (de) 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
EP2659881B1 (en) * 2012-04-30 2017-11-29 Tillotts Pharma Ag A delayed release drug formulation
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
EP3542791A1 (en) 2013-10-29 2019-09-25 Tillotts Pharma AG A delayed release drug formulation

Also Published As

Publication number Publication date
RS58735B1 (sr) 2019-06-28
AU2017210577B2 (en) 2018-11-29
EA201491783A1 (ru) 2014-12-30
JOP20200144A1 (ar) 2017-06-16
ES2673931T3 (es) 2018-06-26
CR20190246A (es) 2019-09-03
GEP201706758B (en) 2017-10-25
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
PE20142442A1 (es) 2015-01-28
TR201905226T4 (tr) 2019-05-21
MX2014012887A (es) 2015-05-08
JOP20200146B1 (ar) 2023-09-17
PT3278792T (pt) 2019-05-23
LT2659881T (lt) 2018-02-12
TN2014000441A1 (en) 2016-03-30
CN110237056A (zh) 2019-09-17
EP3278792B1 (en) 2019-02-20
US10226430B2 (en) 2019-03-12
EA032514B1 (ru) 2019-06-28
CN110200949A (zh) 2019-09-06
US9364440B2 (en) 2016-06-14
SI2844220T1 (sl) 2019-05-31
TWI618547B (zh) 2018-03-21
AU2017210571B2 (en) 2018-11-29
CR20190245A (es) 2019-07-29
MX367127B (es) 2019-08-06
EA032811B1 (ru) 2019-07-31
BR122019022551B1 (pt) 2022-07-19
TW201720430A (zh) 2017-06-16
US11517534B2 (en) 2022-12-06
US20150125525A1 (en) 2015-05-07
CU24304B1 (es) 2018-01-10
CN104302274A (zh) 2015-01-21
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
TWI705833B (zh) 2020-10-01
CO7141433A2 (es) 2014-12-12
ES2720258T3 (es) 2019-07-19
HUE037702T2 (hu) 2018-09-28
ES2655622T3 (es) 2018-02-20
JO3574B1 (ar) 2020-07-05
JP6621661B2 (ja) 2019-12-18
ME03364B (me) 2019-10-20
JOP20200146A1 (ar) 2022-10-30
HRP20180965T1 (hr) 2018-08-10
SI3278792T1 (sl) 2019-06-28
CN104271113B (zh) 2019-03-22
US10272048B2 (en) 2019-04-30
EP2844222B1 (en) 2019-11-13
NZ725409A (en) 2018-05-25
JOP20200145A1 (ar) 2022-10-30
PT2844222T (pt) 2019-12-30
CA3052460A1 (en) 2013-11-07
BR112014026935A2 (pt) 2017-06-27
AU2013255913A1 (en) 2014-11-13
CA3052460C (en) 2022-06-07
WO2013164315A1 (en) 2013-11-07
EP2659881A1 (en) 2013-11-06
EA201491781A1 (ru) 2014-12-30
PL2844222T3 (pl) 2020-03-31
WO2013164316A1 (en) 2013-11-07
PH12014502340A1 (en) 2014-12-22
EP2844220A1 (en) 2015-03-11
MX366677B (es) 2019-07-19
EP3189830B1 (en) 2018-05-23
KR20150004910A (ko) 2015-01-13
GEP201706753B (en) 2017-10-25
KR102102198B1 (ko) 2020-04-21
CO7151506A2 (es) 2014-12-29
LT2844222T (lt) 2019-12-27
SMT201800095T1 (it) 2018-03-08
EP3187171B1 (en) 2024-09-25
PT3189830T (pt) 2018-10-19
US20200214987A1 (en) 2020-07-09
CA2871017A1 (en) 2013-11-07
LT3189830T (lt) 2018-07-10
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
RS57431B1 (sr) 2018-09-28
TN2014000442A1 (en) 2016-03-30
RS56839B1 (sr) 2018-04-30
TWI700102B (zh) 2020-08-01
RS58625B1 (sr) 2019-05-31
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
HUE046628T2 (hu) 2020-03-30
CY1120492T1 (el) 2019-07-10
CA3080035A1 (en) 2013-11-07
HUE043238T2 (hu) 2019-08-28
CN106983735A (zh) 2017-07-28
PL3189830T3 (pl) 2018-11-30
PH12014502339A1 (en) 2014-12-22
ES2761341T3 (es) 2020-05-19
ES2987408T3 (es) 2024-11-14
PT2844220T (pt) 2019-03-27
EP2844222A1 (en) 2015-03-11
NZ629262A (en) 2017-01-27
JP2015515965A (ja) 2015-06-04
BR112014026933B1 (pt) 2022-07-19
DK2844222T3 (da) 2019-12-09
SMT201800360T1 (it) 2018-09-13
JOP20200148A1 (ar) 2022-10-30
US20150132380A1 (en) 2015-05-14
CA2871016A1 (en) 2013-11-07
KR20200073296A (ko) 2020-06-23
KR20200075024A (ko) 2020-06-25
CY1122475T1 (el) 2021-01-27
ME03641B (me) 2020-07-20
TW202037370A (zh) 2020-10-16
US9814681B2 (en) 2017-11-14
PH12014502340B1 (en) 2014-12-22
CL2014002795A1 (es) 2015-02-13
BR112014026933A2 (pt) 2017-06-27
GEP201706736B (en) 2017-09-25
KR20150004911A (ko) 2015-01-13
JP2015515964A (ja) 2015-06-04
SA115370043B1 (ar) 2016-05-24
CY1120215T1 (el) 2018-12-12
AU2013255913B2 (en) 2017-08-31
MX362529B (es) 2019-01-23
MY169161A (en) 2019-02-19
GEP201706759B (en) 2017-10-25
SI2844222T1 (sl) 2020-02-28
TR201903569T4 (tr) 2019-04-22
EP2844220B1 (en) 2019-01-23
HUE036187T2 (hu) 2018-06-28
AU2017210577A1 (en) 2017-08-24
LT3278792T (lt) 2019-05-10
SMT202000014T1 (it) 2020-03-13
US20140056980A1 (en) 2014-02-27
JP6621662B2 (ja) 2019-12-18
KR20190127986A (ko) 2019-11-13
CR20140486A (es) 2015-01-19
SMT201900215T1 (it) 2019-05-10
KR20190127984A (ko) 2019-11-13
SG11201406799XA (en) 2014-11-27
PL3278792T3 (pl) 2019-09-30
AU2017210571A1 (en) 2017-08-24
EP3189830A1 (en) 2017-07-12
JOP20200148B1 (ar) 2023-09-17
US20170266117A1 (en) 2017-09-21
RS59697B1 (sr) 2020-01-31
CY1121609T1 (el) 2020-05-29
CU20140123A7 (es) 2015-02-26
EP3278792A1 (en) 2018-02-07
TW201343202A (zh) 2013-11-01
KR102177773B1 (ko) 2020-11-12
JOP20200147A1 (ar) 2022-10-30
AU2013255914B2 (en) 2017-08-31
MX373249B (es) 2020-05-12
MY190392A (en) 2022-04-20
DK3189830T3 (en) 2018-07-16
UY34772A (es) 2013-11-29
PT2659881T (pt) 2018-01-29
KR102104070B1 (ko) 2020-04-24
CN110237056B (zh) 2022-03-08
SMT201900252T1 (it) 2019-07-11
CR20140485A (es) 2015-01-19
NO2659881T3 (es) 2018-04-28
DK3278792T3 (da) 2019-05-06
HUE042833T2 (hu) 2019-07-29
LT2844220T (lt) 2019-04-10
EP3187171C0 (en) 2024-09-25
CN110200949B (zh) 2021-11-16
SG11201406798WA (en) 2014-11-27
NZ629260A (en) 2017-01-27
US11534406B2 (en) 2022-12-27
JOP20200147B1 (ar) 2023-09-17
AU2013255914A1 (en) 2014-11-13
CA2871016C (en) 2023-03-21
EP3187171A1 (en) 2017-07-05
PL2659881T3 (pl) 2018-05-30
CN104271113A (zh) 2015-01-07
PH12014502339B1 (en) 2014-12-22
PE20190625A1 (es) 2019-04-26
PE20150129A1 (es) 2015-02-13
SI3189830T1 (en) 2018-08-31
JOP20200145B1 (ar) 2023-09-17
TR201809416T4 (tr) 2018-07-23
AR090898A1 (es) 2014-12-17
DK2659881T3 (en) 2018-02-05
US20170035698A1 (en) 2017-02-09
ES2714448T3 (es) 2019-05-28
DK2844220T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
CL2014002796A1 (es) Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal.
CL2013001316A1 (es) Composicion que comprende micro-organismo probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
CL2013001655A1 (es) Compuestos bifenilicos sustituidos; composicion farmaceutica; y uso en el tratamiento o prevencion de fibrosis pulmonar, renal, hepatica o cutanea.
CL2013002698A1 (es) Sistema de union vertical para un sustrato que tiene una primera y una segunda superficie principal opuestas entre si que comprende el sistema una primera y una segunda union no simetricas, extendidas a lo largo de dos lados opuestos del sustrato; metodo para fabricar un sustrato y sistema de recubrimiento de superficies.
BR112013011969A2 (pt) sistema de injetor de fluido medicinal
HUE058896T2 (hu) N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
BR112014016889A8 (pt) composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
BR112015002692A2 (pt) revestimento, sistema de revestimento de barreira térmica e método para revestir uma superfície.
EP2710116A4 (en) AVIRULENTE MODIFIED SALMONELLA GALLINARUM STRAINS AND PHARMACEUTICAL COMPOSITION THEREOF
CL2013002971A1 (es) Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas.
CL2013001313A1 (es) Composicion que comprende microorganismos probióticos no replicantes para prevenir o tratar infecciones gastrointestinales
IT1402677B1 (it) Sistema di caricamento di munizioni d'artiglieria.
CL2017001989A1 (es) Formulación de fármaco de liberación retardada. (divisional solicitud 2795-2014)
CL2014003361A1 (es) Profarmaco de ácido fosforamidico del compuesto 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida; composicion farmaceutica y uso en el tratamiento o la prevencion de la arritmia.
HUE050954T2 (hu) Mukózán alkalmazható makrogolok és azok terápiás alkalmazásai
EP3053601A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER WITH CYB5R3 GENE OR PROTEIN AS AN ACTIVE SUBSTANCE
WO2014030052A3 (en) Compositions comprising an antibody and camostat mesylate (cm)
TH159388A (th) สารประกอบแมคโครไซคลิคและวิธีการผลิตของมัน
IT1402795B1 (it) Sistema per la rifinitura e decorazione interna e/o esterna di serramenti.
TH160505A (th) สารประกอบและวิธีสำหรับเสริมการตอบสนองด้วยภูมิคุ้มกันโดยกำเนิดให้เพิ่มขึ้น
TH159902A (es)
Falk Foreword. Biologics of IBD
TH154821A (th) สารประกอบฟิวจ์ริงควิโนลิลไพร์โรโลไพริมิดิล หรือเกลือของสารนี้
CN302550128S (zh) 瓶盖
NI201600077A (es) Sistema de administración farmacológico